Strattera — Medica
attention deficit hyperactivity disorder (ADHD)
Preferred products
- generic atomoxetine capsules
- amphetamine/dextroamphetamine ER capsules (Adderall XR, generic; Mydayis, generic)
- dexmethylphenidate ER capsules (Focalin XR, generic)
- lisdexamfetamine capsules and chewable tablets (Vyvanse, generic)
- methylphenidate ER capsules (Metadate CD, generic; Ritalin LA, generic; Adhansia XR; Aptensio XR)
- amphetamine sulfate tablets (Evekeo)
- amphetamine ER orally disintegrating tablets (Adzenys XR-ODT)
- amphetamine ER oral suspension (Dyanavel XR, Adzenys ER)
- mixed amphetamine salts immediate-release tablets/capsules (Adderall, Adderall XR, generic)
- dextroamphetamine immediate-release tablets/capsules (Dexedrine, Zenzedi, Dexedrine Spansules, generic)
- dextroamphetamine sulfate oral solution (ProCentra, generic)
- methamphetamine tablets (Desoxyn, generic)
- methylphenidate ER tablets/capsules (Adhansia XR, Aptensio XR, Concerta, Metadate CD, Metadate ER, Ritalin LA, Ritalin-SR, generic)
- methylphenidate immediate-release tablets, oral solution, chewable tablets (Ritalin, Methylin, Methylin Chewable, generic)
- dexmethylphenidate immediate-release tablets (Focalin, generic)
- dexmethylphenidate ER capsules (Focalin XR, generic)
- methylphenidate transdermal system (Daytrana)
- methylphenidate ER oral suspension (Quillivant XR, QuilliChew ER)
Initial criteria
- Patient has tried one Step 1 Product (generic atomoxetine capsules or a stimulant medication [amphetamine or methylphenidate/dexmethylphenidate product])
- OR Patient is unable to take a stimulant medication AND unable to swallow whole capsules and tablets according to the prescriber (then approve Qelbree or Onyda XR)
Reauthorization criteria
- Same criteria as initial approval
Approval duration
1 year